Published in Arch Neurol on May 01, 2010
Neuronal autoantigens--pathogenesis, associated disorders and antibody testing. Nat Rev Neurol (2012) 3.20
Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology (2010) 2.31
Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry (2012) 2.21
Autoimmune encephalopathies. Ann N Y Acad Sci (2014) 1.65
Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology (2011) 1.64
Paraneoplastic neurological syndromes. Curr Opin Neurol (2012) 1.29
Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol (2011) 1.28
Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry (2012) 1.16
Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood (2014) 1.06
Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. Neurotherapeutics (2016) 1.02
Autosomal-recessive congenital cerebellar ataxia is caused by mutations in metabotropic glutamate receptor 1. Am J Hum Genet (2012) 0.98
Hodgkin's Lymphoma: A Review of Neurologic Complications. Adv Hematol (2010) 0.97
'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. J Neuroinflammation (2015) 0.94
The Moonwalker mouse: new insights into TRPC3 function, cerebellar development, and ataxia. Cerebellum (2014) 0.94
Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. J Neurol (2012) 0.87
Patient with homer-3 antibodies and cerebellitis. JAMA Neurol (2013) 0.84
Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes. Neurology (2016) 0.82
Neuronal surface antibody-mediated autoimmune encephalitis. Semin Neurol (2014) 0.82
Autoimmune Encephalitis. Eur Neurol Rev (2013) 0.80
Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev (2017) 0.78
Neuronal central nervous system syndromes probably mediated by autoantibodies. Eur J Neurosci (2016) 0.75
Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
Magnetic resonance imaging findings in patients presenting with (sub)acute cerebellar ataxia. Neuroradiology (2015) 0.75
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol (2013) 11.47
Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol (2010) 7.97
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol (2009) 5.75
Radiotherapy for glioblastoma in the elderly. N Engl J Med (2007) 5.64
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol (2009) 4.49
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr (2012) 4.12
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Clinical analysis of anti-Ma2-associated encephalitis. Brain (2004) 3.89
Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain (2008) 3.51
Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol (2014) 3.40
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain (2003) 3.39
Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain (2003) 3.28
Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol (2011) 2.99
Natural history of multiple sclerosis: a unifying concept. Brain (2006) 2.96
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 2.59
Time-window bias in case-control studies: statins and lung cancer. Epidemiology (2011) 2.56
Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol (2002) 2.48
Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain (2012) 2.39
Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology (2014) 2.38
Age at disability milestones in multiple sclerosis. Brain (2006) 2.37
Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology (2013) 2.32
Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry (2012) 2.21
Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet (2007) 2.17
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 2.17
Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol (2003) 2.05
Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol (2003) 2.02
MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke (2006) 1.91
Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol (2012) 1.80
A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol (2010) 1.77
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain (2004) 1.70
CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica (2003) 1.62
Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys (2004) 1.62
Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys (2005) 1.61
Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis. J Neuroimmunol (2004) 1.56
The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thromb Haemost (2013) 1.53
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res (2005) 1.53
Rapidly progressive diffuse Lewy body disease. Mov Disord (2011) 1.52
A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol (2013) 1.50
Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol (2012) 1.50
Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol (2010) 1.49
First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr (2004) 1.48
Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children. Dev Med Child Neurol (2014) 1.47
Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol (2003) 1.47
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Acute-onset chorea, dystonia, and cardiac fibroelastoma in a child: a paraneoplastic association? Mov Disord (2012) 1.44
Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain (2010) 1.42
Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult Scler (2009) 1.41
Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol (2006) 1.40
Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (2010) 1.38
Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol (2011) 1.37
Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain (2002) 1.37
Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol (2006) 1.37
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol (2011) 1.34
Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer (2003) 1.33
In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis (2010) 1.33
MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain (2004) 1.31
SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol (2009) 1.28
Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) (2003) 1.27
The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain (2009) 1.26
Regulation of spine development by semaphorin3A through cyclin-dependent kinase 5 phosphorylation of collapsin response mediator protein 1. J Neurosci (2007) 1.25
From bone marrow to microglia: barriers and avenues. Trends Immunol (2008) 1.25
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler (2013) 1.25
Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol (2010) 1.24
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol (2003) 1.24
Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator. J Neurol Sci (2004) 1.24
Clinical neuropathology practice guide 5-2012: updated guideline for the diagnosis of antineuronal antibodies. Clin Neuropathol (2012) 1.23
A benign form of neuromyelitis optica: does it exist? Arch Neurol (2011) 1.21
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol (2006) 1.21
Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol (2009) 1.20
Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis (2004) 1.19
Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol (2007) 1.17
Factors influencing early admission in a French stroke unit. Stroke (2002) 1.16
Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry (2012) 1.16
Immunoglobulin G antibodies to the N-Methyl-D-aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses. Ann Neurol (2014) 1.13
NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler (2008) 1.12
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain (2011) 1.11
Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol (2005) 1.11
Geographic variations of multiple sclerosis in France. Brain (2010) 1.10
One can prevent post-partum MS relapses by exclusive breast feeding: no. Mult Scler (2013) 1.09
Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann Neurol (2010) 1.08
Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumour. J Neurol Neurosurg Psychiatry (2007) 1.06